Department of Clinical Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
Departement of Social and Administrative Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
BMC Cardiovasc Disord. 2024 Oct 3;24(1):533. doi: 10.1186/s12872-024-04199-x.
The life-threatening diseases known as ACS (acute coronary syndrome) continue to produce considerable rates of morbidity and mortality despite breakthroughs in therapy. The study determined clinical outcome and its predictors in patients at the University of Gondar Comprehensive and Specialized Hospital (UOGCSH), North West Ethiopia.
DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study design was employed at UOGCSH from January 31, 2018 to February 1, 2023. The hospital used a systematic random sampling procedure to select study participants from the medical records of patients in chronic cardiac follow-up clinics.
Exposures were optimal medical therapy (OMT) versus non-optimal medical therapy collected from May to August 2023. Descriptive and analytical statistics were employed to compare study groups. A binary logistic regression model was employed to identify candidate variables for further analysis. Cox's proportional hazard model and log-rank test were employed, with a P-value < 0.05 used to evaluate statistical significance. A five-year all-cause mortality after discharge estimate was displayed by using Kaplan-Meier curves.
Among 422 patients with ACS [mean age, 61.56 (SD = 9.686) years; 54.7% male], of whom only 59.2% (250) received optimal medical therapy at discharge. Age ≥ 65, atrial fibrillation, chronic kidney diseases, and cardiogenic shock were negative independent predictors of optimal medical therapy. On the other hand, male sex was independently associated with the use of optimal medical therapy. All-cause mortality occurred in 16.6% (n = 70) and major adverse cardiac events occurred in 30.8% (n = 130) of patients with a 95% CI of 0.132-0.205 and 0.264-0.355, respectively. Multivariate analyses indicated that OMT was significantly associated with reduced all-cause mortality (aHR: 0.431, 95% CI: 0.222-0.835; P = 0.013).
This study revealed that the use of preventive OMT in patients discharged with acute coronary syndrome was associated with a reduction in all-cause mortality. However, the use of this OMT is suboptimal.
尽管在治疗方面取得了突破,但已知的危及生命的疾病——急性冠脉综合征(ACS)仍然导致相当高的发病率和死亡率。本研究旨在确定在埃塞俄比亚西北部贡德尔大学综合和专科医院(UOGCSH)的患者的临床结局及其预测因素。
设计、地点和参与者:这是一项回顾性队列研究,于 2018 年 1 月 31 日至 2023 年 2 月 1 日在 UOGCSH 进行。该医院采用系统随机抽样程序,从慢性心脏随访诊所患者的病历中选择研究参与者。
暴露因素为最佳药物治疗(OMT)与非最佳药物治疗,于 2023 年 5 月至 8 月收集。采用描述性和分析性统计方法比较研究组。采用二元逻辑回归模型确定进一步分析的候选变量。采用 Cox 比例风险模型和对数秩检验,P 值<0.05 用于评估统计学意义。通过 Kaplan-Meier 曲线显示出院后五年的全因死亡率估计值。
在 422 例 ACS 患者中(平均年龄 61.56(SD=9.686)岁;54.7%为男性),只有 59.2%(250 例)在出院时接受了最佳药物治疗。年龄≥65 岁、心房颤动、慢性肾脏病和心源性休克是 OMT 的负面独立预测因素。另一方面,男性与使用 OMT 独立相关。16.6%(n=70)的患者发生全因死亡,30.8%(n=130)的患者发生主要不良心脏事件,95%CI 分别为 0.132-0.205 和 0.264-0.355。多变量分析表明,OMT 与全因死亡率降低显著相关(aHR:0.431,95%CI:0.222-0.835;P=0.013)。
本研究表明,在出院的急性冠脉综合征患者中使用预防性 OMT 与全因死亡率降低相关,但这种 OMT 的使用并不理想。